Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: Considerations for local treatment

American Journal of Tropical Medicine and Hygiene

Volumn 89, Issue 2, 2013, Pages 359-364

  Blanco, Victor M ^a   Cossio, Alexandra ^a   Martinez, Javier D ^a   Saravia, Nancy Gore ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COLOMBIA; CONTROLLED STUDY; FEMALE; HEAD; HUMAN; INFANT; LOCAL THERAPY; MALE; NECK; NEWBORN; PRACTICE GUIDELINE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; AGE DISTRIBUTION; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; COLOMBIA; FEMALE; HUMANS; INFANT; LEISHMANIASIS, CUTANEOUS; MALE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION;

EID: 84881492507     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.12-0784     Document Type: Article

References (34)

1. Palacios R, Osorio LE, Grajales LF, Ochoa MT, 2001. Treatment failure in children in a randomized clinical trialwith 10 and20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am J Trop Med Hyg 64: 187-193.
2. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo, Saravia NG, 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 195: 602-608.
3. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez- Barraquer I,GarcerantD, PragerM,Osorio L,Rojas MX, PérezM,NichollsRS,Gore SaraviaN, 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684-692.
4. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.
5. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S, 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.AmJ Trop Med Hyg 84: 255-260.
6. Bonfante-Garrido R, Melendez E, Barroeta S, de Alejos MA, Momen H, Cupolillo E, 1992. Cutaneous leishmaniasis in western Venezuela caused by infection with Leishmania venezuelensis and L. braziliensis variants. Trans R Soc Trop Med Hyg 86: 141-148.
7. Bittencourt AL, Barral A, Costa JM, 1996. Tegumentary leishmaniasis in chilhood. Pediatr Dermatol 13: 455-463.
8. Desjeux P, 1991. Information on the Epidemiology and Control of the Leishmaniasis by Country or Territory. Geneva: World Health Organization.
9. GarcíaA, Parrado L, Rojas R, Delgado E, Dujardin R, Reithinger R, 2009. Leishmaniasis in Bolivia: comprehensive review and current status.AmJ Trop Med Hyg 80: 704-711.
10. Oliveira CC, Lacerda HG, Martins DR, Barbosa JD, Monteiro GR, Queiroz JW, Sousa JM, Ximenes MF, Jeronimo SM, 2004. Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface. Acta Trop 90: 155-162.
11. Montoya J, Jaramillo C, Palma G, Gomez T, Segura I, Travi B, 1990. Report of an epidemic outbreak of tegumentary leishmaniasis in a coffee-growing area of Colombia. Mem Inst Oswaldo Cruz 85: 119-121.
12. World Health Organization, 2002. Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec 77: 365-372.
13. World Health Organization, 2010. Control of the Leishmaniasis: Report of the Meeting of the WHO Expert Committee on the Control of Leishmaniasis. Technical Reports Series 949. Geneva: World Health Organization.
14. Weigle K, de Dávalos M, Heredia P, Molineros R, Saravia N, D'Alessandro A, 1987. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: comparison of seven methods. AmJ Trop Med Hyg 36: 489-496.
15. McMahon-Pratt D, David JR, 1981. Monoclonal antibodies that distinguish between New World species of Leishmania. Nature 291: 581-582.
16. Saravia N, Segura I, Holguin A, Santrich C, Valderrama C, Ocampo C, 1988. Epidemiologic, genetic and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 59: 86-94.
17. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG, 1993. Epidemiology of cutaneous leishmaniasis in Colombia: environmental and behavioral risk factors for infection, clinical manifestations, and pathogenicity. J Infect Dis 168: 709-714.
18. Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G Jr, Fernandes O, 1998. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 178: 911-914.
19. Vergel C, Palacios R, Cadena H, Posso C, Valderrama L, Perez M, Walker J, Travi BLT, Saravia NG, 2006. Evidence for Leishmania Viannia in skin and blood of patients before and after treatment. J Infect Dis 194: 503-511.
20. Figueroa RA, Lozano LE, Romero IC, Cardona MT, Prager M, Diaz YR, Tellez JA, Saravia NG, 2009.Detection of Leishmania in unaffected mucosal tissues of patients with American cutaneous leishmaniasis. J InfectDis 200: 638-646.
21. Romero IC, Tellez J, Suárez Y, Cardona MT, Figueroa R, Zelazny A, Saravia NG, 2010. Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis. PLoS Negl Trop Dis 4: e819.
22. de Oliveira Camera P, Junger J, do Espírito Santo Silva Pires F, Mattos M, Oliveira-Neto MP, Fernandes O, Pirmez C, 2006. Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 100: 1112-1117.
23. Ampuero J, Macêdo V, Marsden P, 2006. Clinical findings of tegumentary leishmaniasis in children under five years of age in an endemic area of Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop 39: 22-26.
24. Costa JM, Balby IT, Rocha EJ, da Silva AR, Rebêlo JM, Ferreira LA, Gama ME, Branco Mdos R, Burattini MN, Soares Nde J, 1998. Comparative study of American tegumentary leishmaniasis between childhood and teenagers from the endemic areas Buriticupu, Maranhao and Corte de Pedra, Bahia, Brazil. Rev Soc Bras Med Trop 31: 279-288.
25. Pinto MC, Campbell-Lendrum DH, Lozovei AL, Teodoro U, DaviesCR, 2001.Phlebotomine sandfly responses to carbon dioxide and human odour in the field.Med VetEntomol 15: 132-139.
26. Navin TR, Arana BA, Arana FE, de Mérida AM, Castillo AL, Pozuelos JL, 1990. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 42: 43-50.
27. Lobo IM, Soares MB, Correia TM, de Freitas LA, Oliveira MI, Nakatani M, Netto E, Badaro R, David JR, 2006. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg 100: 642-649.
28. López L, Robayo M, Vargas M, Vélez ID, 2012. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 17: 13-58.
29. Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, Kolaczinski J, David JR. 2005. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40: 1148-1155.
30. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon IK, Hummer KA, Gasser RA Jr, Oster CN, Benson PM. 2010. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 4: e628.
31. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, Cruz M, Gracia L, Villarroel D, Alavi I, Toledo J, Berman J, 2013. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 1255-1260.
32. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, 2009. WR279, 396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.
33. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524-532.
34. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 15: CD004834.